D-0384-2026 Class II Ongoing

Recalled by Rising Pharma Holding, Inc. — East Brunswick, NJ

FDA drug recall D-0384-2026 was initiated by Rising Pharma Holding, Inc. on Mar 3, 2026 and is designated Class II. Reason for recall: Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing The recall status is ongoing. Affected quantity: 1200 bottles.

Recall details

Product Type
Drugs
Report Date
Mar 11, 2026
Initiation Date
Mar 3, 2026
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
1200 bottles

Product description

Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceuticals, Inc., Allendale, NJ 07401, Country of origin: Taiwan, NDC 16571-816-51.

Reason for recall

Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-month long term stability testing

Distribution pattern

Nationwide within the U.S

Code information

Lot #: 1TM0524003A, Exp. Date 09/2026.

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0384-2026
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0384-2026. Report a data issue: hello@regdatalab.com.